A Phase 2 Pilot Feasibility Study of Palbociclib in Combination with Adjuvant Endocrine Therapy for Hormone Receptor Positive Invasive Breast Carcinoma
-
- STATUS
- Not Recruiting
Updated on 19 February 2024
Summary
The purpose of this research is to evaluate a drug called Palbociclib in combination with endocrine therapy as a possible treatment for hormone receptor positive breast cancer.
Description
This is a multi-center, single arm, phase II pilot study. It is a non-randomized, open label study of the feasibility of longer duration combination therapy with palbociclib and adjuvant endocrine therapy in patients with higher-risk HR+ breast cancer.
Details
| Condition | breast cancer |
|---|---|
| Age | 18years - 100years |
| Clinical Study Identifier | TX4618 |
| Last Modified on | 19 February 2024 |
How understandable was the trial content above?
Hard to understand
Easy to understand
Similar trials to consider
Loading...
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteerStudy Definition
WikipediaAdd a private note
- Select a piece of text.
- Add notes visible only to you.
- Send it to people through a passcode protected link.